Clinical trials: Endometrial Cancer
Endometrial Cancer
Single-Port Hysterectomy (R-SPH) Using the Da Vinci SP System in Low-Risk Endometrial Cancer
Patients with clinically confirmed endometrioid endometrial cancer at FIGO stage IA-IB were eligible for robotic single-port hysterectomy (R-SPH).
- Trial name
- NCT06681831
- Testing
- DaVinci SP
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Endometrial Cancer
Developing a MRI-based Deep Learning Model to Predict MMR Status
In order to develop a convenient, cheap and comprehensive method to preoperatively predict dMMR and reduce the number of people requiring dMMR-related immunohistochemical or genetic testing after surgery, this study aims to…
- Trial name
- NCT05783986
- Testing
- randomly divided
- Volunteers
- 600 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Endometrial Carcinoma, Endometrial Carcinoma Stage III
GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High-Risk Endometrial Cancer
GYNORYLAQ-VLINIVAL is an Early Phase I, non-randomized, single-arm, open-label clinical trial enrolling 40 patients with high-risk or recurrent endometrial carcinoma.
- Trial name
- GYNORYLAQ™ (NCT07316361)
- Testing
- • Biological: GYNORYLAQ-TM Personalized Neoantigenic Peptide Vaccine
- Where
- Greece
- Volunteers
- 40 people
- Sponsor
- Biogenea Pharmaceuticals Ltd.
Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I
Progesterone Therapeutic Regimen Plus Statins in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia
To explore the treatment efficacy of Progesterone Therapeutic Regimen Plus Statins in patients with atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EEC) for conservative treatment.
- Trial name
- NCT06102863
- Testing
- statins (oral atorvastatin calcium tablet 20mg/ day; Or rosuvastatin 5mg/ day; Or pivastatin 2mg/ day);
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Peking University People's Hospital
Endometrial Hyperplasia
Comparison of Dilatation & Curettage and Endometrial Aspiration Biopsy Accuracy in Patients Treated With Progestin for Endometrial Hyperplasia: A Korean Gynecologic Oncology Group Study
A prospective multicenter trial has been started in Korea to evaluate the diagnostic accuracy of endometrial aspiration biopsy compared with D\&C in patients treated with progestin for endometrial hyperplasia (EH).
- Trial name
- NCT02412072
- Where
- South Korea
- Volunteers
- 75 people
- Sponsor
- Korean Gynecologic Oncology Group
Cancer
Care of Cancer Patients With Bowel Injury Caused by Radiation Therapy to the Pelvis
RATIONALE: A step-by-step procedure may help health care practitioners diagnose and treat cancer patients with bowel injury symptoms caused by radiation therapy.
- Trial name
- NCT00737230
- Testing
- educational intervention, questionnaire administration, assessment of therapy complications
- Where
- United Kingdom
- Volunteers
- 250 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Endometrial Cancer
Flavopiridol in Treating Patients With Recurrent or Persistent Endometrial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of flavopiridol in treating patients who have recurrent or…
- Trial name
- NCT00023894
- Testing
- alvocidib
- Where
- 54 sites in United States, Australia and 3 more
- Sponsor
- Gynecologic Oncology Group
Endometrial Cancer Stage
Investigation Of Receptivity Markers For Endometrial Cancer Treatment Development
Hyaluronan is an extracellular matrix protein that is involved in cell-cell and cell-matrix interactions. Hyaluronan performs this activity through hyaladherins, which are intracellular and extracellular receptors.
- Trial name
- NCT05914844
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Manisa Celal Bayar University
Postmenopausal Bleeding
Evaluation of DNA Methylation Markers for Endometrial Cancer Risk-stratification Using Patient-collected Urine and Vaginal Samples and Clinician-collected Cervical Samples From Women With Postmenopausal Bleeding
The goal of this observational study is to investigate the clinical utility of DNA-methylation testing in urine and vaginal samples collected by patients and cervical samples collected by clinicians, to determine the risk of…
- Trial name
- NCT07400835
- Testing
- DNA-methylation testing in patient-collected urine and vaginal samples and clinician-collected cervical samples
- Where
- 3 sites in Denmark
- Volunteers
- 600 people
- Sponsor
- University of Aarhus
Cancer, Endometrial Cancer
Adaptive Radiotherapy for Safe Hypofractionation
This phase II, registry-based cohort-multiple randomized controlled trial (cmRCT) evaluates whether daily online adaptive radiotherapy (ART) enables the safe delivery of hypofractionated, iso-biologically equivalent (EQD2)…
- Conditions
- Cancer, Endometrial Cancer, Prostate Cancer, Cervical Cancer
- Trial name
- ART-Hypo (NCT07516210)
- Testing
- Adaptive Hypofractionated Radiotherapy, Standard-of-care Radiotherapy
- Where
- Canada
- Volunteers
- 264 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Endometrial Cancer
Strain-elastography in Endometrial Cancer
Strain elastography is a novel, non-invasive, easy applicable method to determine the tissue characteristics of benign or malign lesions in various organs.
- Trial name
- NCT06623916
- Testing
- Endometrial Cancer Survivors
- Where
- Turkey (Türkiye)
- Volunteers
- 63 people
- Sponsor
- Alper seyhan
Endometrial Cancer
Mifepristone for Patients With Endometrial Cancer and LGESS
Primary Objectives: 1. To determine the antitumor activity of Mifepristone (RU-486) in patients with advanced or recurrent endometrioid adenocarcinoma or low grade endometrial stromal sarcoma (LGESS). 2.
- Trial name
- NCT00505739
- Testing
- Mifepristone
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- M.D. Anderson Cancer Center
Microsatellite Instability, Lynch Syndrome
MSI in Circulatory DNA of Endometrial Cancer
This study aims to analyze the microsatellite instability (MSI) in the circulatory tumor DNA and in the tumor tissue in the patients diagnosed with uterine endometrial cancer.
- Conditions
- Microsatellite Instability, Lynch Syndrome, Endometrial Cancer, Circulating Tumor Cell
- Trial name
- NCT03744962
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Lei Li
Endometrial Cancer
Liposomal Doxorubicin in Treating Patients With Advanced or Recurrent Endometrial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of liposomal doxorubicin in treating women who have…
- Trial name
- NCT00005861
- Testing
- pegylated liposomal doxorubicin hydrochloride
- Where
- 10 sites in United States
- Sponsor
- Gynecologic Oncology Group
Mixed Tumor, Mullerian
Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus
The goal of this clinical research study is to find out if the combination of paclitaxel and carboplatin chemotherapy can shrink or slow the growth of mixed mullerian tumors (MMMT) of the uterus.
- Trial name
- NCT00502203
- Testing
- Carboplatin, Paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Endometrial Cancer
Comparison Between High and Low Level Para-aortic Lymphadenectomy in High and Intermediate Risk Endometrial Carcinoma
Endometrial cancer (EC) is the most frequent gynecological malignancy in developed countries and ranks second in incidence worldwide after cervical cancer, accounting for nearly 10% of cancers in women .
- Trial name
- NCT07306195
- Testing
- high level para-aortic lymphadenectomy, low level para-aortic lymphadenectomy
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Ahmed Aouf
Breast Neoplasms, Endometrial Neoplasms
Chemotherapy With Whole Body Hyperthermia to Treat Resistant Breast, Endometrial, Cervical and Ovarian Cancers
Thermal therapy (hyperthermia of heat) can increase the effect of chemotherapy treatments. By itself, thermal therapy can also kill cancer cells.
- Conditions
- Breast Neoplasms, Endometrial Neoplasms, Cervix Neoplasms, Ovarian Neoplasms
- Trial name
- NCT00178802
- Testing
- thermochemotherapy (with 5-fluorouracil/interferon-a/liposomal doxorubicin)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Gynaecological Oncology, Gynaecological Malignancies
Laparotomy vs Laparoscopy in Endometrial Cancer Staging
Endometrial cancer is one of the most common gynecological malignancies worldwide. Surgical staging is the cornerstone of management and traditionally performed via laparotomy.
- Conditions
- Gynaecological Oncology, Gynaecological Malignancies, Laparoscopic
- Trial name
- NCT07546825
- Testing
- laparoscopic surgical staging, open surgical staging
- Where
- Egypt
- Volunteers
- 48 people
- Sponsor
- Assiut University
Endometrial Cancer
Pemetrexed Disodium in Treating Patients With Persistent or Recurrent Endometrial Cancer
RATIONALE: Drugs used in chemotherapy such as pemetrexed disodium work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00087100
- Testing
- pemetrexed disodium
- Where
- 23 sites in United States
- Volunteers
- 51 people
- Sponsor
- Gynecologic Oncology Group